GEMFIBROZIL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H22O3
Molecular Weight	250.3334
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1

InChI

InChIKey=HEMJJKBWTPKOJG-UHFFFAOYSA-N

InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C15H22O3
Molecular Weight	250.3334
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB01241
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018422s055lbl.pdf

Gemfibrozil, a fibric acid antilipemic agent similar to clofibrate, is used to treat hyperlipoproteinemia and as a second-line therapy for type IIb hypercholesterolemia. It acts to reduce triglyceride levels, reduce VLDL levels, reduce LDL levels (moderately), and increase HDL levels (moderately). Gemfibrozil increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. It does so by activating Peroxisome proliferator-activated receptor-alpha (PPARα) 'transcription factor ligand', a receptor that is involved in metabolism of carbohydrates and fats, as well as adipose tissue differentiation. This increase in the synthesis of lipoprotein lipase thereby increases the clearance of triglycerides. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Gemfibrozil also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. Gemfibrozil is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Solute carrier organic anion transporter family member 1B1 32 Target ID: CHEMBL1697668 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16316932	Inhibitor 8228	12.5 µM [Ki]
Cytochrome P450 2C9 50 Target ID: CHEMBL3397 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16299161	Inhibitor 8228	30.0 µM [IC50]
Cytochrome P450 2C8 18 Target ID: CHEMBL3721 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16176562	Inhibitor 8228	30.4 µM [Ki]
Peroxisome proliferator-activated receptor alpha 62 Target ID: CHEMBL239 Sources: http://www.drugbank.ca/drugs/DB01241	Agonist 2662	59.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyperlipidemia 80 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018422s055lbl.pdf	Primary		Approved 8360	LOPID Approved Use LOPID (gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides Launch Date 3.77654411E11
Coronary heart disease 23 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018422s055lbl.pdf	Preventing		Approved 8360	LOPID Approved Use LOPID (gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides Launch Date 3.77654411E11

C_max

Value	Dose	Co-administered	Analyte	Population
28 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19648824	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		GEMFIBROZIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17400 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01736254	600 mg single, oral dose: 600 mg route of administration: oral experiment type: single co-administered:		GEMFIBROZIL plasma	Homo sapiens population: healthy age: sex: food status:

AUC

Value	Dose	Co-administered	Analyte	Population
104 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19648824	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		GEMFIBROZIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
4.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19648824	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		GEMFIBROZIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	Disc. AE: Depression, Flushing... AEs leading to discontinuation/dose reduction: Depression (1.1%) Flushing (1.1%) Nausea (2.2%) Vomiting (1.1%) Rash (1.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	Disc. AE: Abdominal cramps, Abnormal liver function tests... AEs leading to discontinuation/dose reduction: Abdominal cramps Abnormal liver function tests Diarrhea CPK increased Joint pain Muscle pain Nausea Vomiting Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13

AEs

AE	Significance	Dose	Population
Depression	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Flushing	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Rash	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Vomiting	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Nausea	2.2% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Abdominal cramps	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Abnormal liver function tests	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
CPK increased	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Diarrhea	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Joint pain	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Muscle pain	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Nausea	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Vomiting	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1579	inhibitor 1752	inhibitor 1837

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 781 OATP2B1 122 OATP1B3 700 OAT3 636 MRP2 367 P-gp 1437 CYP2C8 901 CYP2C19 1463 CYP1A2 1509 CYP2A6 704 CYP2E1 876	P-gp 1527 UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A6 307 UGT1A7 236 UGT1A8 283 UGT1A9 380 UGT1A10 290 UGT2B4 249 UGT2B7 389 UGT2B15 203 UGT2B17 213

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2A6 736	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
CYP2D6 1875	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
CYP2E1 964	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
CYP3A4 1909	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
MRP2 459	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/17523051/\|https://pubmed.ncbi.nlm.nih.gov/16316932/	no
P-gp 1626	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/16316932/\|https://pubmed.ncbi.nlm.nih.gov/14698041/	no
OAT3 638	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/21383204/\|https://pubmed.ncbi.nlm.nih.gov/17455113/	yes [Ki 1.5 uM]
OATP1B1 796	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/25653502/\|https://pubmed.ncbi.nlm.nih.gov/23139378/\|https://pubmed.ncbi.nlm.nih.gov/17523051/\|https://pubmed.ncbi.nlm.nih.gov/16316932/\|https://pubmed.ncbi.nlm.nih.gov/17470528/	yes [Ki 14.2 uM]
CYP2C9 1803	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11719730/ \|https://pubmed.ncbi.nlm.nih.gov/11602509/	yes [Ki 5.8 uM]	yes (co-administration study) Comment: [PMID:11719730]:Gemfibrozil modestly increases the plasma concentrations of glimepiride. This may be caused by inhibition of CYP2C9. Sources: https://pubmed.ncbi.nlm.nih.gov/11719730/ \|https://pubmed.ncbi.nlm.nih.gov/11602509/
CYP1A2 1673	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	yes
CYP2C19 1537	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	yes
OATP1B3 709	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/25653502/\|https://pubmed.ncbi.nlm.nih.gov/17470528/	yes
OATP2B1 125	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/17470528/	yes
CYP2C8 955	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/25941268/\|https://pubmed.ncbi.nlm.nih.gov/22472994/	yes	yes (co-administration study) Comment: [PMID:22472994]: CYP2C8 inactivation by gemfibrozil caused dose-dependent increases in AUC of repaglinide Sources: https://pubmed.ncbi.nlm.nih.gov/25941268/\|https://pubmed.ncbi.nlm.nih.gov/22472994/

Drug as victim

Target	Modality	Activity
UGT2B7 389	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	major
P-gp 1527	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/14698041/	no
UGT1A10 290	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A4 347	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A6 307	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A7 236	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A8 283	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT2B15 203	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A1 418	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT1A3 422	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT1A9 380	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT2B17 213	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT2B4 249	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5296	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5296
ChemicalBook	CB9154247	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9154247
MolPort	MolPort-001-794-413	https://www.molport.com/shop/molecule-link/MolPort-001-794-413
Selleck Chemicals	Gemfibrozil(Lopid)	http://www.selleckchem.com/products/Gemfibrozil(Lopid).html
ZINC	ZINC000001530641	http://zinc15.docking.org/substances/ZINC000001530641
eMolecules	538915	https://www.emolecules.com/cgi-bin/more?vid=538915

PubMed

Title	Date	PubMed




Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy.	1999 Apr 1	10190540
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.	1999 Jun	10364093
Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.	2000	11173785
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.	2001	11795072
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.	2001	11464448
Treatment of dyslipoproteinemia in the metabolic syndrome.	2001	11453042
Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men.	2001 Aug	11477498
Bayer decides to withdraw cholesterol lowering drug.	2001 Aug 18	11509419
Altered expression of the carboxylesterases ES-4 and ES-10 by peroxisome proliferator chemicals.	2001 Aug 28	11522369
Treatment for the procoagulant state in type 2 diabetes.	2001 Dec	11727398
Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?	2001 Dec	11722675
Determination of drugs in surface water and wastewater samples by liquid chromatography-mass spectrometry: methods and preliminary results including toxicity studies with Vibrio fischeri.	2001 Dec 14	11771838
Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney.	2001 Feb	11159800
The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia.	2001 Feb 1	11164856
Short-term gemfibrozil treatment reverses lipid profile and peroxidation but does not alter blood glucose and tissue antioxidant enzymes in chronically diabetic rats.	2001 Jan	11216864
Stimulatory effect of clofibrate and gemfibrozil administration on the formation of fatty acid esters of estradiol by rat liver microsomes.	2001 Jan	11123380
Normocholesterolaemic dyslipidaemia: is there a role for fibrates?	2001 Jan 15	11245504
Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.	2001 Jul	11583069
Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia.	2001 Jun	11385362
Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles.	2001 Jun	11376633
[Helsinki Heart Study].	2001 Mar	11347103
Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.	2001 Mar 28	11268266
Choice of lipid-regulating drugs.	2001 May 28	11378632
Attenuation by fibrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells.	2001 Nov	11816722
Effect of trans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara on experimental hypertriglyceridaemia and hypercholesterolaemia induced by Triton WR 1339 (tyloxapol) in mice.	2001 Nov	11731925
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.	2001 Nov	11719730
Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.	2001 Nov	11715936
Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?	2001 Nov	11711005
Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?	2001 Nov	11694861
Effects of fenofibrate and gemfibrozil on plasma homocysteine.	2001 Nov 24	11734263
Cyclic nucleotides in platelets of genetically hypertriglyceridemic and hypertensive rats. Thrombin and nitric oxide responses are unrelated to plasma triglyceride levels.	2001 Oct 1	11583736
[Cholestatic hepatitis caused by gemfibrozil].	2001 Sep	11767440
Cerivastatin and gemfibrozil-associated rhabdomyolysis.	2001 Sep	11573847
Bayer pulls cerivastatin (Baycol) from market.	2001 Sep 4	11563216
Sexual dysfunction secondary to gemfibrozil.	2002 Jan	11794424
Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.	2002 Jan 28	11802751

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose for adults is 1200 mg administered in two divided doses 30 minutes before the morning and evening meals

Route of Administration: Oral

In Vitro Use Guide

Sustained potent reduction of [Ca²⁺]i in cultured rat VSMCs was observed with Gemfibrozil 50mg/L

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:50:46 UTC 2023` Edited by `admin` on `Wed Jul 05 22:50:46 UTC 2023`
Record UNII	Q8X02027X3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GEMFIBROZIL

Official Name

English

GEMFIBROZIL [IARC]

Common Name

English

Gemfibrozil [WHO-DD]

Common Name

English

GEMFIBROZIL [HSDB]

Common Name

English

2,2-DIMETHYL-5-(2,5-XYLYLOXY) VALERIC ACID

Systematic Name

English

gemfibrozil [INN]

Common Name

English

GEMFIBROZIL [EP MONOGRAPH]

Common Name

English

GEMFIBROZIL [MART.]

Common Name

English

GEMFIBROZIL [USAN]

Common Name

English

GEMFIBROZIL [USP-RS]

Common Name

English

GEMFIBROZIL [JAN]

Common Name

English

NSC-757024

Code

English

GEMFIBROZIL [ORANGE BOOK]

Common Name

English

GEMFIBROZIL [MI]

Common Name

English

GEMFIBROZIL [INCI]

Common Name

English

CI-719

Code

English

GEMFIBROZIL [USP MONOGRAPH]

Common Name

English

PENTANOIC ACID, 5-(2,5-DIMETHYLPHENOXY)-2,2-DIMETHYL-

Common Name

English

LOPID

Brand Name

English

GEMFIBROZIL [VANDF]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

834821